Located at Arkansas State University, BioStrategies LC is a small biotech company originally formed to develop the two founder's enzyme replacement drug delivery/targeting discoveries for the benefit of patients suffering from life-terminating rare genetic diseases: the now FDA approved drug Elelyso used to treat Gaucher disease, a lysosomal storage disease. The company works on enzyme replacement therapies (ERTs) and lectin-based protein delivery systems designed to increase ERT drug effectiveness through delivery to cells and tissues in the body that are not adequetly treated by existing ERT drugs and delivery mechanisms. The principals have a continuing commitment to solve current treatment limitations that have reduced the efficacy of these drugs in hard to treat organs such as the brain, heart, and skeletal system. Target Market(s): Physicians and pharmaceutical companies targeting patients suffering from currently incurable genetic rare diseases.
